Lanzhou Foci Pharmaceutical Chairman Resigns

Lanzhou Foci Pharmaceutical (SHE:002644) Chairman Shi Aiguo has resigned due to a job transfer, according to a filing with the Shenzhen Stock Exchange on Tuesday. A successor to Shi is yet to be named

MT NewswiresApr 10 16:18

Foci Pharmaceuticals (002644): Short-term performance is under pressure and waiting for the implementation of a new strategy

Incident: 1) On April 9, the company released its 2023 annual report. In 2023, the company achieved operating income of 1,163 billion yuan (+11.58%) and realized net profit of 67.1887 million yuan (-38.1)

長城證券Apr 10 00:00

Foci Pharmaceutical (002644.SZ): Net profit for 2023 fell 38.16% to 67.1897 million yuan, and plans to distribute 10 to 0.3 yuan

On April 9, Ge Longhui Pharmaceutical (002644.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,163 billion yuan, an increase of 11.58%; net profit attributable to shareholders of listed companies was 67.1897 million yuan, a year-on-year decrease of 38.16%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 509.378 million yuan, a year-on-year decrease of 7.57%; basic income per share was 0.1316 yuan; it plans to distribute cash dividends of 0.3 yuan (tax included) for every 10 shares to all shareholders.

Gelonghui FinanceApr 9 19:08

Foci Pharmaceutical (002644): OTC price increase for branded traditional Chinese medicines accelerates market development in South China

Incident: 1) On March 11, the company issued the “Notice on Price Adjustment of the Company's Main Proprietary Chinese Medicine Products”. Due to reasons such as rising raw materials and production costs, the company decided to start dealing with proprietary Chinese medicines from March 11, 2024

長城證券Mar 18 00:00

A-share traditional Chinese medicine stocks opened actively, and Forci Pharmaceuticals rose or stopped

Gelonghui, March 12 | Foci Pharmaceutical and Xintian Pharmaceutical rose and stopped, Zoli Pharmaceutical rose more than 15%, and Guangdong Wannianqing, Taiji Group, and Panlong Pharmaceutical followed suit. According to the news, Forci Pharmaceuticals announced that due to reasons such as rising raw materials and production costs, the company decided to adjust the factory price of its main proprietary Chinese medicine products starting March 11, 2024, with an average price increase of 9%. In addition, Zuoli Pharmaceuticals expects net profit of 137 million yuan to 147 million yuan for the first quarter, an increase of 40.58%-50.84% over the previous year.

Gelonghui FinanceMar 12 09:28

Express News | Foci Pharmaceutical: Factory price increase of 9% for its main proprietary Chinese medicine products

BreakingsMar 11 16:24